Jan. 14 at 6:06 PM
$OMDA Canaccord Genuity has reiterated its Buy rating and
$28.00 price target on Omada Health Inc (NASDAQ:OMDA) following the company’s preliminary fourth-quarter and annual results. This target represents a 74% upside from the current price of
$16.12, which is currently trading near InvestingPro’s calculated Fair Value. The stock has seen 4 analysts revise their earnings upwards for the upcoming period.
Omada Health announced preliminary Q4 2025 and annual revenue ranges that exceeded both Canaccord’s and consensus estimates. The company reported enrolled members of 886,000, representing 55% year-over-year growth, which marks an acceleration from the 52.8% growth posted in the third quarter. This growth trajectory is notable for a company with a market capitalization of
$933 million and trailing twelve-month revenue of
$232.3 million.